User login
PARIS — Patients with early rheumatoid arthritis had greater improvements with abatacept treatment than did those with longstanding disease, according to a new post hoc analysis of two clinical trials.
In the first report of the efficacy of this selective T-cell costimulation modulator in patients whose disease duration is 2 years or less and who have an inadequate response to methotrexate but are biologically naive, almost half were in disease remission at year 3, according to Dr. Yusuf Yazici.
This study included 462 patients from both a phase II trial and a double-blind placebo controlled trial who had been randomized to receive abatacept 10 mg/kg once monthly and who had entered a long-term extension phase, with assessments at years 1 and 3.
Patients' mean age was 55 years, 76% were female, and 82% were rheumatoid factor positive. Mean baseline disease activity score 28 (DAS28) was 6.4, health assessment questionnaire (HAQ) was 1.5, and C-reactive protein (CRP) was 3.2 mg/dL.
Among the entire cohort, 25% of the patients were in DAS28 remission at year 1, as were 36% at year 3, said Dr. Yazici of New York University, and director of the Seligman Center for Advanced Therapeutics, NYU Hospital for Joint Diseases, New York.
A total of 108 patients had early disease, while 159 had longstanding disease. A comparison of these groups showed that 46% of those with early disease were in remission at year 3, compared with 31% of those with longstanding disease, Dr. Yusuf Yazici said at the annual European Congress of Rheumatology.
Remission rates were also significantly better for the early disease group at year 1 and year 3, as were ACR 70 rates. Moreover, among the early disease group, significantly more patients had clinically meaningful improvements in their HAQ scores. (See box.)
“These data support the use of abatacept in biologic-naive patients who have early disease and who have had an inadequate response to methotrexate,” Dr. Yazici concluded.
Dr. Yazici disclosed that he is a consultant for BMS, Roche, Celgene, UCB, Pfizer, and Centocor.
ELSEVIER GLOBAL MEDICAL NEWS
PARIS — Patients with early rheumatoid arthritis had greater improvements with abatacept treatment than did those with longstanding disease, according to a new post hoc analysis of two clinical trials.
In the first report of the efficacy of this selective T-cell costimulation modulator in patients whose disease duration is 2 years or less and who have an inadequate response to methotrexate but are biologically naive, almost half were in disease remission at year 3, according to Dr. Yusuf Yazici.
This study included 462 patients from both a phase II trial and a double-blind placebo controlled trial who had been randomized to receive abatacept 10 mg/kg once monthly and who had entered a long-term extension phase, with assessments at years 1 and 3.
Patients' mean age was 55 years, 76% were female, and 82% were rheumatoid factor positive. Mean baseline disease activity score 28 (DAS28) was 6.4, health assessment questionnaire (HAQ) was 1.5, and C-reactive protein (CRP) was 3.2 mg/dL.
Among the entire cohort, 25% of the patients were in DAS28 remission at year 1, as were 36% at year 3, said Dr. Yazici of New York University, and director of the Seligman Center for Advanced Therapeutics, NYU Hospital for Joint Diseases, New York.
A total of 108 patients had early disease, while 159 had longstanding disease. A comparison of these groups showed that 46% of those with early disease were in remission at year 3, compared with 31% of those with longstanding disease, Dr. Yusuf Yazici said at the annual European Congress of Rheumatology.
Remission rates were also significantly better for the early disease group at year 1 and year 3, as were ACR 70 rates. Moreover, among the early disease group, significantly more patients had clinically meaningful improvements in their HAQ scores. (See box.)
“These data support the use of abatacept in biologic-naive patients who have early disease and who have had an inadequate response to methotrexate,” Dr. Yazici concluded.
Dr. Yazici disclosed that he is a consultant for BMS, Roche, Celgene, UCB, Pfizer, and Centocor.
ELSEVIER GLOBAL MEDICAL NEWS
PARIS — Patients with early rheumatoid arthritis had greater improvements with abatacept treatment than did those with longstanding disease, according to a new post hoc analysis of two clinical trials.
In the first report of the efficacy of this selective T-cell costimulation modulator in patients whose disease duration is 2 years or less and who have an inadequate response to methotrexate but are biologically naive, almost half were in disease remission at year 3, according to Dr. Yusuf Yazici.
This study included 462 patients from both a phase II trial and a double-blind placebo controlled trial who had been randomized to receive abatacept 10 mg/kg once monthly and who had entered a long-term extension phase, with assessments at years 1 and 3.
Patients' mean age was 55 years, 76% were female, and 82% were rheumatoid factor positive. Mean baseline disease activity score 28 (DAS28) was 6.4, health assessment questionnaire (HAQ) was 1.5, and C-reactive protein (CRP) was 3.2 mg/dL.
Among the entire cohort, 25% of the patients were in DAS28 remission at year 1, as were 36% at year 3, said Dr. Yazici of New York University, and director of the Seligman Center for Advanced Therapeutics, NYU Hospital for Joint Diseases, New York.
A total of 108 patients had early disease, while 159 had longstanding disease. A comparison of these groups showed that 46% of those with early disease were in remission at year 3, compared with 31% of those with longstanding disease, Dr. Yusuf Yazici said at the annual European Congress of Rheumatology.
Remission rates were also significantly better for the early disease group at year 1 and year 3, as were ACR 70 rates. Moreover, among the early disease group, significantly more patients had clinically meaningful improvements in their HAQ scores. (See box.)
“These data support the use of abatacept in biologic-naive patients who have early disease and who have had an inadequate response to methotrexate,” Dr. Yazici concluded.
Dr. Yazici disclosed that he is a consultant for BMS, Roche, Celgene, UCB, Pfizer, and Centocor.
ELSEVIER GLOBAL MEDICAL NEWS